A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer
File(s)tau-09-S4-S489.pdf (570.79 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Although radiotherapy to the prostate for cancer is effective, recurrence occurs in 10–15% within 5 years. Traditional salvage treatments for men with radiorecurrent prostate cancer comprise of watchful waiting (WW) with or without androgen deprivation therapy (ADT) or radical prostatectomy (RP). Neither strategy provides ideal therapeutic ratios. Salvage focal ablation is an emerging option. We performed a systematic review of the Medline and Embase databases for studies reporting outcomes of focal salvage brachytherapy (sBT), cryotherapy (sCT) or high-intensity focused ultrasound (sHIFU) for radiorecurrent prostate cancer (conception to April 2019). Results were screened for inclusion against predetermined eligibility criteria. Certain data were extracted, including rates of biochemical disease-free survival (BDFS), metastasis, conversion to second-line therapies and adverse events. Of a total 134 articles returned from the search, 15 studies (14 case series and 1 comparative study) reported outcomes after focal sBT [5], sCT [7] and sHIFU [3]. Cohort size varied depending on intervention, with eligible studies of sBT being small case series. Median follow-up ranged from 10 to 56 months. Although pre-salvage demographics were similar [median age range, 61–75 years; prostate-specific antigen (PSA) range, 2.8–5.5 ng/mL], there was heterogeneity in patient selection, individual treatment protocols and outcome reporting. At 3 years, BDFS ranged from 61% to 71.4% after sBT, 48.1–72.4% after sCT and 48% after sHIFU. Only studies of sCT reported 5-year BDFS, which ranged from 46.5% to 54.4%. Rates of metastasis were low after all salvage modalities, as were conversion to second-line therapies (although this was poorly reported). Grade 3 adverse events were rare. This systematic review indicates that salvage focal ablation of radiorecurrent prostate cancer provides acceptable oncological outcomes and is well tolerated. Unfortunately, there is heterogeneity in the study design of existing evidence. Level 1 research comparing salvage focal therapies to existing whole-gland strategies is needed to further establish the role of these promising treatments.
Date Issued
2020-03-01
Date Acceptance
2019-08-06
ISSN
2223-4691
Publisher
AME Publishing Company
Start Page
S489
End Page
S499
Journal / Book Title
Translational andrology and urology
Volume
9
Issue
Suppl. 4
Copyright Statement
© Translational Andrology and Urology. All rights reserved. Open access under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Wellcome Trust
University College London Hospitals Charity
Imperial Health Charity
The Urology Foundation
Medical Research Council (MRC)
British Medical Association
Imperial College Healthcare NHS Trust- BRC Funding
University College London Hospitals Charity
Identifier
http://tau.amegroups.com/article/view/28825
Grant Number
204998/Z/16/Z
1348
RF18/100021
WSST_P73887
WSST_P70374
T P Gunton (2018)
RDB04
WSSY_P84790
Publication Status
Published
OA Location
http://tau.amegroups.com/article/view/28825